Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oleoylethanolamide + LipiSperse is a combination dietary supplement containing **oleoylethanolamide (OEA)**, a naturally occurring bioactive lipid mediator, and **LipiSperse**, a lipid-based dispersion delivery technology designed to enhance the oral bioavailability of lipophilic compounds. OEA acts as a peroxisome proliferator-activated receptor-alpha (PPAR-α) agonist, regulating food intake, satiety, lipid metabolism, and exhibiting antioxidant effects. LipiSperse improves the dispersibility and absorption of OEA in the gastrointestinal tract. This specific combination is primarily under investigation for metabolic benefits, such as modulating incretin hormone release (e.g., GLP-1 via GPR119 activation), changes in insulin, glucose, DPP-4, glucagon, and appetite-related endpoints. The combination has been studied in healthy volunteers and is being developed as a dietary supplement for potential use in weight management and metabolic health support[1][2][3][4][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oleoylethanolamide + LipiSperse.